Treatment of Multiple Sclerosis Relapses

Regina Berkovich, MD, PhD, discusses systemic steroids and approach to diagnosis as factors for the new algorithm in treating MS relapses.

Corticosteroids as a first-line treatment approach, along with dosing and alternatives to systemic steroids, are explored in MS relapses.

A breakdown of the ACTH protein is provided in repository corticotropic injection use in relapsing MS.

Regina Berkovich, MD, PhD, highlights the use of ACTH in a second-line or third-line setting in MS relapses and the impact on B lymphocytes.

Costs are considered in ACTH use as well as the differentiating factor in adverse effects of ACTH versus systemic steroids in relapsing MS treatment.

An age-old scale, EDSS, is examined with its limitations in MS [multiple sclerosis], and major outcomes measures such as MRI imaging are discussed.

Dr Berkovich provides final thoughts on barriers to adoption, community advice, and future improvements in outcomes measures in the treatment of MS [multiple sclerosis] relapses.

Thomas P. Leist, MD, PhD, discusses the importance of treating relapsed multiple sclerosis and the new treatment algorithm published at CMSC (Consortium of Multiple Sclerosis Centers).

An expert neurologist considers how to assess a relapsed patient, the goals of first-line therapy, and the value of administering early treatment.

The role of corticosteroids in treating patients with relapsed multiple sclerosis, and alternative first-line treatments.

Thomas P. Leist, MD, PhD, provides an overview of the use of repository corticotropic injections in treating patients with relapsed multiple sclerosis.

Advice for community neurologists: best practices for patient follow-up after receiving therapy, and incorporating new treatment algorithms.
SAP Partner Banner